Cargando…
Cardiotoxic effects of angiogenesis inhibitors
The development of new therapies for cancer has led to dramatic improvements in survivorship. Angiogenesis inhibitors represent one such advancement, revolutionising treatment for a wide range of malignancies. However, these drugs are associated with cardiovascular toxicities which can impact optima...
Autores principales: | Dobbin, Stephen J.H., Petrie, Mark C., Myles, Rachel C., Touyz, Rhian M., Lang, Ninian N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812690/ https://www.ncbi.nlm.nih.gov/pubmed/33404052 http://dx.doi.org/10.1042/CS20200305 |
Ejemplares similares
-
Differential effects of cyclo-oxygenase 1 and 2 inhibition on angiogenesis inhibitor-induced hypertension and kidney damage
por: Mirabito Colafella, Katrina M., et al.
Publicado: (2022) -
ACE2/Ang-(1-7)/Mas1 axis and the vascular system: vasoprotection to COVID-19-associated vascular disease
por: Kuriakose, Jithin, et al.
Publicado: (2021) -
Notch3 signalling and vascular remodelling in pulmonary arterial hypertension
por: Morris, Hannah E., et al.
Publicado: (2019) -
The anti-cancer drug dabrafenib is not cardiotoxic and inhibits cardiac remodelling and fibrosis in a murine model of hypertension
por: Meijles, Daniel N., et al.
Publicado: (2021) -
Skin-specific mechanisms of body fluid regulation in hypertension
por: Chen, Jun Yu, et al.
Publicado: (2023)